Publication

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Hanemaaijer, S. H., Kok, I. C., Fehrmann, R. S. N., van der Vegt, B., Gietema, J. A., Plaat, B. E. C., van Vugt, M. A. T. M., Vergeer, M. R., Leemans, C. R., Langendijk, J. A., Voortman, J., Buter, J. & Oosting, S. F., 5-Jun-2020, In : Frontiers in Oncology. 10, 9 p., 761.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Hanemaaijer, S. H., Kok, I. C., Fehrmann, R. S. N., van der Vegt, B., Gietema, J. A., Plaat, B. E. C., van Vugt, M. A. T. M., Vergeer, M. R., Leemans, C. R., Langendijk, J. A., Voortman, J., Buter, J., & Oosting, S. F. (2020). Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 10, [761]. https://doi.org/10.3389/fonc.2020.00761

Author

Hanemaaijer, Saskia H ; Kok, Iris C ; Fehrmann, Rudolf S N ; van der Vegt, Bert ; Gietema, Jourik A ; Plaat, Boudewijn E C ; van Vugt, Marcel A T M ; Vergeer, Marije R ; Leemans, C René ; Langendijk, Johannes A ; Voortman, Jens ; Buter, Jan ; Oosting, Sjoukje F. / Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. In: Frontiers in Oncology. 2020 ; Vol. 10.

Harvard

Hanemaaijer, SH, Kok, IC, Fehrmann, RSN, van der Vegt, B, Gietema, JA, Plaat, BEC, van Vugt, MATM, Vergeer, MR, Leemans, CR, Langendijk, JA, Voortman, J, Buter, J & Oosting, SF 2020, 'Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma', Frontiers in Oncology, vol. 10, 761. https://doi.org/10.3389/fonc.2020.00761

Standard

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. / Hanemaaijer, Saskia H; Kok, Iris C; Fehrmann, Rudolf S N; van der Vegt, Bert; Gietema, Jourik A; Plaat, Boudewijn E C; van Vugt, Marcel A T M; Vergeer, Marije R; Leemans, C René; Langendijk, Johannes A; Voortman, Jens; Buter, Jan; Oosting, Sjoukje F.

In: Frontiers in Oncology, Vol. 10, 761, 05.06.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Hanemaaijer SH, Kok IC, Fehrmann RSN, van der Vegt B, Gietema JA, Plaat BEC et al. Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology. 2020 Jun 5;10. 761. https://doi.org/10.3389/fonc.2020.00761


BibTeX

@article{ebed6dd7f3ab4886b16c89f0b7880799,
title = "Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma",
abstract = "Background:Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, around one-third of the patients cannot complete cisplatin because of toxicity. Carboplatin plus 5-fluorouracil (carbo-5FU) is another accepted treatment option with a different toxicity profile. We compared tolerability and efficacy of concomitant carbo-5FU and cisplatin. Patients and Methods:We conducted a retrospective analysis of LA-HNSCC patients treated with CRT in two Dutch cancer centers between 2007 and 2016. All patients received intensity-modulated radiotherapy. One center routinely administered carboplatin 300-350 mg/m(2)at day 1, 22, and 43 followed by 5FU 600 mg/m(2)/day for 96 h. The other center used cisplatin 100 mg/m(2)at day 1, 22, and 43. The primary endpoint of this study was chemotherapy completion rate. Secondary endpoints included overall survival (OS), disease-free survival (DFS), locoregional control (LRC) and distant metastasis-free interval (DMFS), toxicity, and unplanned admissions. Results:In the carbo-5FU cohort (n= 211), 60.2% of the patients completed chemotherapy vs. 76.7% (p<0.001) of the patients in the cisplatin cohort (n= 223). Univariate analysis showed a higher risk of death in the carbo-5FU cohort [hazard ratio (HR) 1.53, 95% CI, 1.09-2.14,p= 0.01] with a 3-year OS of 65.4 vs. 76.5% for cisplatin. OS was independently associated with T and N stage and p16 status, but not with chemotherapy regimen (HR 1.08, 95% CI, 0.76-1.55,p= 0.65). Three-year DFS was 70.0% for carbo-5FU vs. 78.6% for cisplatin (HR 1.37, 95% CI, 0.93-2.01,p= 0.05). A similar outcome was observed for both LRC (HR 1.27, 95% CI, 0.74-2.09,p= 0.4) and DMFS (HR 1.08, 95% CI 0.62-1.90,p= 0.77). The risk of discontinuation for chemotherapy-associated toxicity was higher in the carbo-5FU cohort than in the cisplatin cohort (relative risk = 1.69). Conclusion:LA-HNSCC patients treated with concomitant carbo-5FU completed chemotherapy less frequently than patients treated with cisplatin. Treatment regimen was not an independent prognostic factor for OS.",
keywords = "area under the concentration-time curve, carboplatin 5-flourouracil, chemoradiotherapy, cisplatin, comparison, head and neck squamous cell carcinoma, locally advanced head and neck squamous cell carcinoma, HUMAN-PAPILLOMAVIRUS, RADIATION-THERAPY, CHEMORADIATION, CHEMOTHERAPY, RADIOTHERAPY, CANCER, TRIAL",
author = "Hanemaaijer, {Saskia H} and Kok, {Iris C} and Fehrmann, {Rudolf S N} and {van der Vegt}, Bert and Gietema, {Jourik A} and Plaat, {Boudewijn E C} and {van Vugt}, {Marcel A T M} and Vergeer, {Marije R} and Leemans, {C Ren{\'e}} and Langendijk, {Johannes A} and Jens Voortman and Jan Buter and Oosting, {Sjoukje F}",
note = "Copyright {\textcopyright} 2020 Hanemaaijer, Kok, Fehrmann, van der Vegt, Gietema, Plaat, van Vugt, Vergeer, Leemans, Langendijk, Voortman, Buter and Oosting.",
year = "2020",
month = jun,
day = "5",
doi = "10.3389/fonc.2020.00761",
language = "English",
volume = "10",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media SA",

}

RIS

TY - JOUR

T1 - Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

AU - Hanemaaijer, Saskia H

AU - Kok, Iris C

AU - Fehrmann, Rudolf S N

AU - van der Vegt, Bert

AU - Gietema, Jourik A

AU - Plaat, Boudewijn E C

AU - van Vugt, Marcel A T M

AU - Vergeer, Marije R

AU - Leemans, C René

AU - Langendijk, Johannes A

AU - Voortman, Jens

AU - Buter, Jan

AU - Oosting, Sjoukje F

N1 - Copyright © 2020 Hanemaaijer, Kok, Fehrmann, van der Vegt, Gietema, Plaat, van Vugt, Vergeer, Leemans, Langendijk, Voortman, Buter and Oosting.

PY - 2020/6/5

Y1 - 2020/6/5

N2 - Background:Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, around one-third of the patients cannot complete cisplatin because of toxicity. Carboplatin plus 5-fluorouracil (carbo-5FU) is another accepted treatment option with a different toxicity profile. We compared tolerability and efficacy of concomitant carbo-5FU and cisplatin. Patients and Methods:We conducted a retrospective analysis of LA-HNSCC patients treated with CRT in two Dutch cancer centers between 2007 and 2016. All patients received intensity-modulated radiotherapy. One center routinely administered carboplatin 300-350 mg/m(2)at day 1, 22, and 43 followed by 5FU 600 mg/m(2)/day for 96 h. The other center used cisplatin 100 mg/m(2)at day 1, 22, and 43. The primary endpoint of this study was chemotherapy completion rate. Secondary endpoints included overall survival (OS), disease-free survival (DFS), locoregional control (LRC) and distant metastasis-free interval (DMFS), toxicity, and unplanned admissions. Results:In the carbo-5FU cohort (n= 211), 60.2% of the patients completed chemotherapy vs. 76.7% (p<0.001) of the patients in the cisplatin cohort (n= 223). Univariate analysis showed a higher risk of death in the carbo-5FU cohort [hazard ratio (HR) 1.53, 95% CI, 1.09-2.14,p= 0.01] with a 3-year OS of 65.4 vs. 76.5% for cisplatin. OS was independently associated with T and N stage and p16 status, but not with chemotherapy regimen (HR 1.08, 95% CI, 0.76-1.55,p= 0.65). Three-year DFS was 70.0% for carbo-5FU vs. 78.6% for cisplatin (HR 1.37, 95% CI, 0.93-2.01,p= 0.05). A similar outcome was observed for both LRC (HR 1.27, 95% CI, 0.74-2.09,p= 0.4) and DMFS (HR 1.08, 95% CI 0.62-1.90,p= 0.77). The risk of discontinuation for chemotherapy-associated toxicity was higher in the carbo-5FU cohort than in the cisplatin cohort (relative risk = 1.69). Conclusion:LA-HNSCC patients treated with concomitant carbo-5FU completed chemotherapy less frequently than patients treated with cisplatin. Treatment regimen was not an independent prognostic factor for OS.

AB - Background:Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, around one-third of the patients cannot complete cisplatin because of toxicity. Carboplatin plus 5-fluorouracil (carbo-5FU) is another accepted treatment option with a different toxicity profile. We compared tolerability and efficacy of concomitant carbo-5FU and cisplatin. Patients and Methods:We conducted a retrospective analysis of LA-HNSCC patients treated with CRT in two Dutch cancer centers between 2007 and 2016. All patients received intensity-modulated radiotherapy. One center routinely administered carboplatin 300-350 mg/m(2)at day 1, 22, and 43 followed by 5FU 600 mg/m(2)/day for 96 h. The other center used cisplatin 100 mg/m(2)at day 1, 22, and 43. The primary endpoint of this study was chemotherapy completion rate. Secondary endpoints included overall survival (OS), disease-free survival (DFS), locoregional control (LRC) and distant metastasis-free interval (DMFS), toxicity, and unplanned admissions. Results:In the carbo-5FU cohort (n= 211), 60.2% of the patients completed chemotherapy vs. 76.7% (p<0.001) of the patients in the cisplatin cohort (n= 223). Univariate analysis showed a higher risk of death in the carbo-5FU cohort [hazard ratio (HR) 1.53, 95% CI, 1.09-2.14,p= 0.01] with a 3-year OS of 65.4 vs. 76.5% for cisplatin. OS was independently associated with T and N stage and p16 status, but not with chemotherapy regimen (HR 1.08, 95% CI, 0.76-1.55,p= 0.65). Three-year DFS was 70.0% for carbo-5FU vs. 78.6% for cisplatin (HR 1.37, 95% CI, 0.93-2.01,p= 0.05). A similar outcome was observed for both LRC (HR 1.27, 95% CI, 0.74-2.09,p= 0.4) and DMFS (HR 1.08, 95% CI 0.62-1.90,p= 0.77). The risk of discontinuation for chemotherapy-associated toxicity was higher in the carbo-5FU cohort than in the cisplatin cohort (relative risk = 1.69). Conclusion:LA-HNSCC patients treated with concomitant carbo-5FU completed chemotherapy less frequently than patients treated with cisplatin. Treatment regimen was not an independent prognostic factor for OS.

KW - area under the concentration-time curve

KW - carboplatin 5-flourouracil

KW - chemoradiotherapy

KW - cisplatin

KW - comparison

KW - head and neck squamous cell carcinoma

KW - locally advanced head and neck squamous cell carcinoma

KW - HUMAN-PAPILLOMAVIRUS

KW - RADIATION-THERAPY

KW - CHEMORADIATION

KW - CHEMOTHERAPY

KW - RADIOTHERAPY

KW - CANCER

KW - TRIAL

U2 - 10.3389/fonc.2020.00761

DO - 10.3389/fonc.2020.00761

M3 - Article

C2 - 32582534

VL - 10

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 761

ER -

ID: 128522018